Literature DB >> 16718768

Platelet-activating factor in cirrhotic liver and hepatocellular carcinoma.

Muriel Mathonnet1, Bernard Descottes, Denis Valleix, Véronique Truffinet, Francois Labrousse, Yves Denizot.   

Abstract

AIM: Platelet-activating factor (PAF) is a pro-inflammatory and angiogenic lipid mediator. Here we aimed to investigate levels of PAF, lyso-PAF (the PAF precursor), phospholipase A(2) (PLA(2), the enzymatic activity generating lyso-PAF), acetylhydrolase activity (AHA, the PAF degrading enzyme) and PAF receptor (PAF-R) transcripts in cirrhotic liver and hepatocellular carcinoma (HCC).
METHODS: Twenty-nine patients with HCC were enrolled in this study. Cirrhosis was present in fourteen patients and seven had no liver disease. Tissue PAF levels were investigated by a platelet-aggregation assay. Lyso-PAF was assessed after its chemical acetylation into PAF. AHA was determined by degradation of [(3)H]-PAF. PLA(2) levels were assessed by EIA. PAF-R transcripts were investigated using RT-PCR.
RESULTS: Elevated amounts of PAF and PAF-R transcripts 1 (leukocyte-type) were found in cirrhotic tissues as compared with non-cirrhotic ones. Higher amounts of PAF and PAF-R transcripts 1 and 2 (tissue-type) were found in HCC tissues as compared with non-tumor tissues. PLA(2), lyso-PAF and AHA levels were not changed in cirrhotic tissues and HCC.
CONCLUSION: While the role of PAF is currently unknown in liver physiology, this study suggests its potential involvement in the inflammatory network found in the cirrhotic liver and in the angiogenic response during HCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16718768      PMCID: PMC4130990          DOI: 10.3748/wjg.v12.i17.2773

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  39 in total

1.  Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis.

Authors:  Y Yang; E M Nemoto; S A K Harvey; V M Subbotin; C R Gandhi
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

2.  Letter: Prostaglandins and the unfavourable cervix.

Authors:  A Calder; M P Embrey
Journal:  Lancet       Date:  1973-12-08       Impact factor: 79.321

Review 3.  Platelet-activating factor acetylhydrolase (PAF-AH).

Authors:  Hiroyuki Arai; Hiroyuki Koizumi; Junken Aoki; Keizo Inoue
Journal:  J Biochem       Date:  2002-05       Impact factor: 3.387

4.  Phospholipid transmethylation and choline phosphotransferase in microsomal fraction of human diseased liver.

Authors:  Y Niwa; T Sakane; M Ichikawa; T Kondo; S Taniguchi
Journal:  J Hepatol       Date:  1986       Impact factor: 25.083

5.  Phosphorylation of STAT-3 in response to basic fibroblast growth factor occurs through a mechanism involving platelet-activating factor, JAK-2, and Src in human umbilical vein endothelial cells. Evidence for a dual kinase mechanism.

Authors:  Dayanand D Deo; T William Axelrad; Everett G Robert; Victor Marcheselli; Nicolas G Bazan; Jay D Hunt
Journal:  J Biol Chem       Date:  2002-04-08       Impact factor: 5.157

6.  Tissue concentrations of platelet-activating factor in colorectal carcinoma: inverse relationships with Dukes' stage of patients.

Authors:  Yves Denizot; Alain Gainant; Laurence Guglielmi; Stephane Bouvier; Pierre Cubertafond; Murielle Mathonnet
Journal:  Oncogene       Date:  2003-10-16       Impact factor: 9.867

7.  Kupffer cells are a major source of increased platelet activating factor in the CCl4-induced cirrhotic rat liver.

Authors:  Yongping Yang; Stephen A K Harvey; Chandrashekhar R Gandhi
Journal:  J Hepatol       Date:  2003-08       Impact factor: 25.083

8.  Local estrogen formation by nontumoral, cirrhotic, and malignant human liver tissues and cells.

Authors:  Luigi A M Castagnetta; Biagio Agostara; Giuseppe Montalto; Lucia Polito; Ildegarda Campisi; Annalisa Saetta; Toru Itoh; Bin Yu; Shiuan Chen; Giuseppe Carruba
Journal:  Cancer Res       Date:  2003-08-15       Impact factor: 12.701

9.  Estrogen enhances angiogenesis through a pathway involving platelet-activating factor-mediated nuclear factor-kappaB activation.

Authors:  Kook Heon Seo; Hyun-Suk Lee; Bongnam Jung; Hyun-Mi Ko; Jung-Hwa Choi; Sung Jun Park; Il-Hwan Choi; Hern-Ku Lee; Suhn-Young Im
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

Review 10.  Platelet-activating factor and normal or leukaemic haematopoiesis.

Authors:  Yves Denizot; Laurence Guglielmi; Magali Donnard; Franck Trimoreau
Journal:  Leuk Lymphoma       Date:  2003-05
View more
  4 in total

Review 1.  The Potential Role of Dietary Platelet-Activating Factor Inhibitors in Cancer Prevention and Treatment.

Authors:  Ronan Lordan; Alexandros Tsoupras; Ioannis Zabetakis
Journal:  Adv Nutr       Date:  2019-01-01       Impact factor: 8.701

2.  Lysophosphatidylcholine acyltransferase1 overexpression promotes oral squamous cell carcinoma progression via enhanced biosynthesis of platelet-activating factor.

Authors:  Tomomi Shida-Sakazume; Yosuke Endo-Sakamoto; Motoharu Unozawa; Chonji Fukumoto; Ken Shimada; Atsushi Kasamatsu; Katsunori Ogawara; Hidetaka Yokoe; Masashi Shiiba; Hideki Tanzawa; Katsuhiro Uzawa
Journal:  PLoS One       Date:  2015-03-24       Impact factor: 3.240

Review 3.  Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives.

Authors:  Ronan Lordan; Alexandros Tsoupras; Ioannis Zabetakis; Constantinos A Demopoulos
Journal:  Molecules       Date:  2019-12-03       Impact factor: 4.411

Review 4.  Tissue Specific Promoters in Colorectal Cancer.

Authors:  A R Rama; A Aguilera; C Melguizo; O Caba; J Prados
Journal:  Dis Markers       Date:  2015-11-15       Impact factor: 3.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.